Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer, The Lancet Infectious Diseases, vol.9, issue.11, pp.699-710, 2009. ,
DOI : 10.1016/S1473-3099(09)70234-8
Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection), Current Opinion in Infectious Diseases, vol.23, issue.5, pp.445-455, 2010. ,
DOI : 10.1097/QCO.0b013e32833c2209
Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans, Antimicrobial Agents and Chemotherapy, vol.49, issue.8, pp.3182-3186, 2005. ,
DOI : 10.1128/AAC.49.8.3182-3186.2005
Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease), Antimicrobial Agents and Chemotherapy, vol.51, issue.11, pp.4029-4035, 2007. ,
DOI : 10.1128/AAC.00175-07
Should antibiotics be given for Buruli ulcer?, The Lancet, vol.375, issue.9715, pp.618-619, 2010. ,
DOI : 10.1016/S0140-6736(10)60169-9
Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment of Mycobacterium ulcerans Disease, Antimicrobial Agents and Chemotherapy, vol.54, issue.9, pp.3678-3685, 2010. ,
DOI : 10.1128/AAC.00299-10
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial, The Lancet, vol.375, issue.9715, pp.664-672, 2010. ,
DOI : 10.1016/S0140-6736(09)61962-0
Mycolactone: A Polyketide Toxin from Mycobacterium ulcerans Required for Virulence, Science, vol.283, issue.5403, pp.854-857, 1999. ,
DOI : 10.1126/science.283.5403.854
Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria, Natural Product Reports, vol.45, issue.3, pp.447-454, 2008. ,
DOI : 10.1039/b803101k
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730631
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans, Nature Reviews Microbiology, vol.4, issue.1, pp.50-60, 2009. ,
DOI : 10.1093/molbev/msm092
Detection of Mycolactone A/B in Mycobacterium ulcerans???Infected Human Tissue, PLoS Neglected Tropical Diseases, vol.2, issue.1, p.577, 2010. ,
DOI : 10.1371/journal.pntd.0000577.t001
Mycolactone Diffuses from Mycobacterium ulcerans???Infected Tissues and Targets Mononuclear Cells in Peripheral Blood and Lymphoid Organs, PLoS Neglected Tropical Diseases, vol.23, issue.10, p.325, 2008. ,
DOI : 10.1371/journal.pntd.0000325.g006
Highly sensitive, operationally simple, cost/time effective detection of the mycolactones from the human pathogen Mycobacterium ulcerans, Chemical Communications, vol.66, issue.9, pp.1410-1412, 2010. ,
DOI : 10.1039/b924896j
Structure elucidation of a novel family of mycolactone toxins from the frog pathogen Mycobacterium sp. MU128FXT by mass spectrometry, Chem Commun, vol.14, pp.4306-4308, 2005. ,
Infection in the Peripheral Blood of Patients with Buruli Ulcer Disease, The Journal of Infectious Diseases, vol.200, issue.11, pp.1675-84, 2009. ,
DOI : 10.1086/646615
URL : https://hal.archives-ouvertes.fr/pasteur-01402286
Dynamics of the Cytokine Response to Mycobacterium ulcerans during Antibiotic Treatment for M. ulcerans Disease (Buruli Ulcer) in Humans, Clinical and Vaccine Immunology, vol.16, issue.1, pp.61-65, 2009. ,
DOI : 10.1128/CVI.00235-08
Systemic suppression of interferon-?? responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans, Journal of Leukocyte Biology, vol.79, issue.6, pp.1150-1156, 2006. ,
DOI : 10.1189/jlb.1005581
Laboratory diagnosis of Buruli ulcer disease, Future Microbiology, vol.5, issue.3, pp.363-370, 2010. ,
DOI : 10.2217/fmb.10.3
Effects of sodium chlorate on toxin production by Escherichia coli O157:H7, Curr Issues Intest Microbiol, vol.5, pp.19-22, 2004. ,
All-Oral Antibiotic Treatment for Buruli Ulcer: A Report of Four Patients, PLoS Neglected Tropical Diseases, vol.189, issue.11, p.770, 2010. ,
DOI : 10.1371/journal.pntd.0000770.t001
The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function, J Immunol, vol.163, pp.3928-3935, 1999. ,
Mycolactone Suppresses T Cell Responsiveness by Altering Both Early Signaling and Posttranslational Events, The Journal of Immunology, vol.184, issue.3, pp.1436-1444, 2010. ,
DOI : 10.4049/jimmunol.0902854
URL : https://hal.archives-ouvertes.fr/pasteur-00594632
toxin mycolactone, The Journal of Experimental Medicine, vol.22, issue.6, pp.1395-1403, 2007. ,
DOI : 10.1016/0022-1759(94)90236-4
URL : https://hal.archives-ouvertes.fr/pasteur-01402321
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin, Cellular Microbiology, vol.34, issue.8, pp.1187-1196, 2005. ,
DOI : 10.1016/S0140-6736(99)01156-3
Mycolactone Inhibits Monocyte Cytokine Production by a Posttranscriptional Mechanism, The Journal of Immunology, vol.182, issue.4, pp.2194-2202, 2009. ,
DOI : 10.4049/jimmunol.0802294
infection (Buruli ulcer), Expert Opinion on Biological Therapy, vol.162, issue.2, pp.187-200, 2009. ,
DOI : 10.1038/sj.cdd.4401168